Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

We have strong indications that voter turnout will be off the charts, with record numbers of mail-in votes and lengthy ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives ...

Nearly a dozen candidates are up for City Council seats representing northeast, central and south central Oxnard.

An unrenovated unit in the Bloomingdale’s building sold for $1.02 million, highlighting depreciation in Chicago’s downtown ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...